Antisense modulation of C-reactive protein expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
Claims33
A compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding C-reactive protein, wherein the compound comprises at least an 8 nucleobase portion of a sequence selected from any of SEQ ID NOs:
- 10, 11, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 26, 34, 35, 36, 37, 38, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 54, and wherein the compound inhibits the expression of C-reactive protein.
A compound comprising a chimeric oligonucleotide 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding C-reactive protein, wherein the compound comprises at least an 8 nucleobase portion of a sequence of SEQ ID NO:23, and wherein the compound inhibits the expression of C-reactive protein.
Dependencies are inferred from the claim text.